Skip to main content

Table 2 Time to treatment failure on AAP across different patient subgroups based on the period of time between castration and mCRPC diagnosis

From: Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

Time between bilateral orchiectomy or ADT treatment and mCRPC diagnosis Percentile Estimate of Time to Treatment Failure on AAP (months) (95% CI) Logrank Test p-value
< 12 months (n = 87) 75 11.9 (10.0–14.0) < 0.0001
50 7.9 (6.6–8.9)
25 4.4 (2.3–5.8)
≥12 months (n = 338) 75 19.7 (16.3–21.2)
50 11.5 (10.0–12.1)
25 5.6 (5.0–6.8)
\